Literature DB >> 23790649

Type 3 thyroplasty for patients with mutational dysphonia.

Kazuhiro Nakamura1, Kiyoaki Tsukahara, Yusuke Watanabe, Daigo Komazawa, Mamoru Suzuki.   

Abstract

INTRODUCTION: The cases consisted of three men with mutational dysphonia, who were aged 37, 35, and 38 years. The speaking fundamental frequencies (SFFs) at the time of the initial diagnosis were 174.6, 170.2, and 180.0 Hz.
METHODS: In all three patients, voice therapy proved ineffective; therefore, surgery was considered. In the anterior-posterior compression test performed preoperatively in the three patients, the voice became low-pitched.
RESULTS: The SFFs decreased postoperatively to 106.9, 115.4, and 87.5 Hz, respectively, in the three patients.
CONCLUSIONS: Type 3 thyroplasty (TP3) is effective for the treatment of patients with mutational dysphonia in whom voice therapy proved unsuccessful.
OBJECTIVE: The SFF of men is high in childhood. At the time of the second pubescent sexual orientation, the frequency usually decreases. However, in some cases, the high-pitched voice of childhood may persist without successful switch to a low-pitched voice during puberty. Thus, there are rare cases of adults with a high-pitched boyish voice. Voice therapy is usually effective for the treatment; however, it may fail in some cases. We performed TP3 for subjects in whom voice therapy proved ineffective. With TP3, the tension of the vocal folds decreases, and the voice becomes low-pitched.
Copyright © 2013 The Voice Foundation. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  Androgen; Framework surgery; Kayser-Gutzmann method; Mutation; Phonosurgery; Voice therapy

Mesh:

Year:  2013        PMID: 23790649     DOI: 10.1016/j.jvoice.2013.05.001

Source DB:  PubMed          Journal:  J Voice        ISSN: 0892-1997            Impact factor:   2.009


  1 in total

1.  Type 3 Thyroplasty for a Patient with Female-to-Male Gender Identity Disorder.

Authors:  Yu Saito; Kazuhiro Nakamura; Shigeto Itani; Kiyoaki Tsukahara
Journal:  Case Rep Otolaryngol       Date:  2018-04-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.